Apr 28, 2022
MEDIT Announces Launch of i700 Intraoral Scanner On April 20, 2022, based on the success of i700 intraoral scanner, MEDIT Corp launched the all new i700 wireless intraoral scanner is light, fast, accurate, and now – wire-free. i700 wireless is a lightweight, wire-free device that offers a smooth and qui...
Read More...
Feb 04, 2022
The discovery of new classes of highly effective drug therapy for prevalent kinds of cardiovascular diseases has witnessed spectacular success in recent decades. The widespread use of these cardiovascular drugs, combined with smoking cessation and nonpharmacological therapy, is thought to be responsible for decreas...
Read More...
Jan 31, 2022
Cardiovascular Diseases (CVDs), primarily constituting heart failure, ischemic heart disease, stroke, are considered as leading global cause of mortality and a major contributor to disability. Over the last 30 years, deaths and disabilities from Cardiovascular Disease have been steadily rising across the globe. Car...
Read More...
Jul 15, 2020
The global healthcare system over the past few decades has transformed exponentially. Today we are living twice as long as our ancestors have lived before. Infrastructure development, technological advancements (such as accurate diagnosis and lesser medical errors), public-private partnerships in healthcare, availa...
Read More...
Feb 21, 2020
The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medical devices. There is a conspicuous disparity in the economic prowess across the countries, but most of them have shown r...
Read More...
Jan 23, 2020
Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision. The drug was approved under P...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper